Sol-Gel Technologies Reports First Quarter 2019 Financial Results and Corporate Update
22 mai 2019 07h05 HE
|
Sol-Gel Technologies Ltd.
Top-line results from Phase III Epsolay® and TWIN trials remain on track; mid-2019 and 4Q19, respectfully Reports top-line generic product revenues of $6.3 million NESS ZIONA, Israel, May 22, 2019...
Sol-Gel Technologies Announces Participation in Upcoming Investor Conference
18 avr. 2019 16h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, April 18, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris
15 avr. 2019 16h28 HE
|
Sol-Gel Technologies Ltd.
Patient enrollment of the pivotal Phase III TWIN clinical trials is on schedule Top-line results expected in the fourth quarter of 2019 NESS ZIONA, Israel, April 15, 2019 (GLOBE NEWSWIRE) --...
Sol-Gel Technologies Reports Full Year 2018 Financial Results and Provides Corporate Update
21 mars 2019 16h05 HE
|
Sol-Gel Technologies Ltd.
Company met all milestones in 2018 and this year expects to report Phase III top-line results for Epsolay® and TWIN, potentially best-in-class papulopustular rosacea and acne vulgaris topical...
Sol-Gel Technologies Announces FDA Approval for Perrigo’s Generic Acyclovir Cream, 5%
06 févr. 2019 09h23 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (Sol-Gel or the Company), a clinical-stage dermatology company focused on identifying, developing and...
Sol-Gel Technologies Appoints John Vieira as U.S. Head of Commercialization
15 janv. 2019 07h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program of TWIN for the Treatment of Acne Vulgaris
17 déc. 2018 07h05 HE
|
Sol-Gel Technologies Ltd.
First subject dosed in pivotal Phase III program evaluating TWIN in subjects with moderate-to-severe acne vulgaris Two Phase III trials expected to enroll a total of approximately 840 subjects ...
Sol-Gel Technologies Announces Sixth Agreement for a Generic Product Candidate with Perrigo
04 déc. 2018 16h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Announces Participation in Upcoming Investor Conference
29 nov. 2018 16h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Reports Third Quarter 2018 Financial Results
13 nov. 2018 16h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...